

## SEQUENCE LISTING

<110> REIMANN, HANSJOERG  
SCHIRMBECK, REINHOLD

<120> METHOD FOR THE PRODUCTION OF (POLY)PEPTIDES BY USING  
TRUNCATED VARIANTS OF THE SV40 LARGE T ANTIGEN WITH AN  
INTACT N TERMINUS

<130> 028622/0106

<140> 09/806,580

<141> 2001-07-02

<150> PCT/EP98/06298

<151> 1998-10-02

<160> 11

<170> PatentIn Ver. 2.1

<210> 1

<211> 5

<212> PRT

<213> Simian virus 40

<400> 1

Lys Lys Lys Arg Lys  
1 5

<210> 2

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 2

Lys Asp Asp Asp Asp Lys  
1 5

<210> 3

<211> 131

<212> PRT

<213> Simian immunodeficiency virus

<400> 3

Met Leu Ile Asp Phe Arg Glu Leu Asn Arg Val Thr Gln Asp Phe Thr  
1 5 10 15

Glu Val Gln Leu Gly Ile Pro His Pro Ala Gly Leu Ala Lys Arg Lys  
20 25 30

Arg Ile Thr Val Leu Asp Ile Gly Asp Ala Tyr Phe Ser Ile Pro Leu  
           35                    40                    45  
 Asp Glu Glu Phe Arg Gln Tyr Thr Ala Phe Thr Leu Pro Ser Val Asn  
       50                    55                    60  
 Asn Ala Glu Pro Gly Lys Arg Tyr Ile Tyr Lys Val Leu Pro Gln Gly  
       65                    70                    75                    80  
 Trp Lys Gly Ser Pro Ala Ile Phe Gln Tyr Thr Met Arg His Val Leu  
                     85                    90                    95  
 Glu Pro Phe Arg Lys Ala Asn Pro Asp Val Thr Leu Val Gln Tyr Met  
                     100                    105                    110  
 Asp Asp Ile Leu Ile Ala Ser Asp Arg Thr Asp Leu Glu His Asp Arg  
           115                    120                    125  
 Val Val Leu  
       130

<210> 4  
 <211> 24  
 <212> DNA  
 <213> Hepatitis B virus

<400> 4  
 tcgaatgggg cagaatcttt ccac

24

<210> 5  
 <211> 24  
 <212> DNA  
 <213> Hepatitis B virus

<400> 5  
 agcttttagtt cagcgcaggg tccc

24

<210> 6  
 <211> 164  
 <212> PRT  
 <213> Hepatitis B virus

<400> 6  
 Met Gly Gln Asn Leu Ser Thr Ser Asn Pro Leu Gly Phe Phe Pro Asp  
       1                    5                    10                    15  
 His Gln Leu Asp Pro Ala Phe Arg Ala Asn Thr Ala Asn Pro Asp Trp  
           20                    25                    30  
 Asp Phe Asn Pro Asn Lys Asp Thr Trp Pro Asp Ala Ala Asn Lys Val  
           35                    40                    45  
 Gly Ala Gly Ala Phe Gly Leu Gly Phe Thr Pro Pro His Gly Gly Leu  
       50                    55                    60

Leu Gly Trp Ser Pro Gln Ala Gln Gly Ile Leu Gln Thr Leu Pro Ala  
 65 70 75 80  
 Asn Pro Pro Pro Ala Ser Thr Asn Arg Gln Ser Gly Arg Gln Pro Thr  
 85 90 95  
 Pro Leu Ser Pro Pro Leu Arg Asn Thr His Pro Gln Ala Met Gln Trp  
 100 105 110  
 Asn Ser Thr Thr Phe His Gln Thr Leu Gln Asp Pro Arg Val Arg Gly  
 115 120 125  
 Leu Tyr Phe Pro Ala Gly Gly Ser Ser Ser Gly Thr Val Asn Pro Val  
 130 135 140  
 Leu Thr Thr Ala Ser Pro Leu Ser Ser Ile Phe Ser Arg Ile Gly Asp  
 145 150 155 160  
 Pro Ala Leu Asn

<210> 7  
 <211> 18  
 <212> PRT  
 <213> Simian immunodeficiency virus

<400> 7  
 Glu Pro Phe Arg Lys Ala Asn Pro Asp Val Thr Leu Val Gln Tyr Met  
 1 5 10 15  
 Asp Asp

<210> 8  
 <211> 4  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Amino acid  
 spacer sequence

<400> 8  
 Asp Ile Glu Phe  
 1

<210> 9  
 <211> 5  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Amino acid  
 stop sequence

<400> 9

Asp Pro Gly Gly Ser  
1 5

<210> 10

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Amino acid  
spacer sequence

<400> 10

Asp Ile Glu Phe Leu Gln Pro Ser Thr Val Ser Ile Ser Leu Ile Arg  
1 5 10 15

<210> 11

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Illustrative  
peptide

<400> 11

Lys Phe Glu Arg Gln  
1 5